cncpt-artikel_lb_atf
Darolutamide – A Viable Long-Term Treatment for nmCRPC
Data presented at ASCO GU 2023 concludes that patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) can safely stay on darolutamide as a viable long-term treatment.